Liquid Metal Hybrid Platform-Mediated Ice–Fire Dual Noninvasive Conformable Melanoma Therapy
Source abstract
Abstract
Cryoablation and photothermal therapy are anticancer therapeutic strategies that destroy tumors by external energy intervention of achieving extremely low temperature and very high temperature in a short time. Compared to traditional surgical resection, radiotherapy, and chemotherapy, they have the advantages of being minimally invasive and having less side effects. However, single cryoablation or photothermal therapy itself has limited therapeutic accuracy, which greatly restricts its clinical application. There is still a common phenomenon that the energy transport at the tumor target site cannot be accurately controlled in space and time dimensions, resulting in limited thermal effect and difficulty to form a conformable treatment area, which will result in low targeted killing efficiency, and tumor cells will become residual and undergo metastasis and recurrence. Herein, a multimodal therapy of cryoablation combined with photothermal therapy was proposed. To further enhance the therapeutic performance, a liquid metal hybrid platform, which is composed of a high-thermal-conductivity liquid metal paste and high-photothermal-conversion-efficiency liquid metal nanoparticles, is mediated for cryoablation and photothermal therapy. Cold and heat synergistic effects are realized through this multimodal therapy. Due to the liquid metal hybrid platform, enhanced antitumor efficacy is achieved in vitro and in vivo. More importantly, the liquid metal hybrid platform-mediated dual therapy is totally noninvasive and does not show obvious systemic toxicity. Collectively, this study has first realized ice (cryoablation)–fire (photothermal therapy) dual noninvasive therapy by one liquid metal platform and demonstrated superior antitumor effect for melanoma treatment. This work explores a new promising multimodal cancer therapy strategy based on the liquid metal platform, which has great potential application in cancer treatment in the future.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
CAS Key Laboratory of Cryogenics, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China
Beijing Key Laboratory of Cryo-Biomedical Engineering, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China
School of Future Technology, University of the Chinese Academy of Sciences, Beijing 100049, China
Funding
Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China
References (47)
Show source-provided references
1. 10.1038/nrc397110.1038/nrc3971 ↗
2. Warren S. · Cancer Res. · 1988 · 4 · 554
3. Gage A. A. · Surg., Gynecol. Obstet. · 1992 · 174 · 73
4. 10.1016/j.hrthm.2015.05.03410.1016/j.hrthm.2015.05.034 ↗
5. 10.1016/j.jamcollsurg.2007.03.00710.1016/j.jamcollsurg.2007.03.007 ↗
6. 10.1146/annurev.bioeng.2.1.15710.1146/annurev.bioeng.2.1.157 ↗
7. 10.1002/1097-0142(19930815)72:4<1291::AID-CNCR2820720423>3.0.CO;2-I10.1002/1097-0142(19930815)72:4<1291::AID-CNCR2820720423>3.0.CO;2-I ↗
8. 10.1016/j.biomaterials.2018.07.02110.1016/j.biomaterials.2018.07.021 ↗
9. 10.1016/0140-7007(91)90003-Y10.1016/0140-7007(91)90003-Y ↗
10. 10.1016/j.nano.2017.11.01810.1016/j.nano.2017.11.018 ↗
11. 10.1006/cryo.1998.211510.1006/cryo.1998.2115 ↗
12. 10.1016/S0090-4295(02)01683-710.1016/S0090-4295(02)01683-7 ↗
13. 10.1006/cryo.2001.233310.1006/cryo.2001.2333 ↗
14. 10.1038/sj.bjc.660030610.1038/sj.bjc.6600306 ↗
15. 10.1016/0011-2240(85)90159-210.1016/0011-2240(85)90159-2 ↗
16. 10.1158/1535-7163.MCT-06-067610.1158/1535-7163.MCT-06-0676 ↗
17. 10.1166/jnn.2009.126410.1166/jnn.2009.1264 ↗
18. 10.1016/j.cryobiol.2004.12.00710.1016/j.cryobiol.2004.12.007 ↗
19. 10.1016/j.cryobiol.2005.01.00110.1016/j.cryobiol.2005.01.001 ↗
20. 10.1039/C2CS35367A10.1039/C2CS35367A ↗
21. 10.1002/advs.20180112210.1002/advs.201801122 ↗
22. 10.1021/acsami.6b1640810.1021/acsami.6b16408 ↗
23. 10.1002/adma.20129006310.1002/adma.201290063 ↗
24. 10.1021/cr400532z10.1021/cr400532z ↗
25. 10.1021/acs.chemmater.6b0294410.1021/acs.chemmater.6b02944 ↗
26. 10.1007/s12551-019-00532-310.1007/s12551-019-00532-3 ↗
27. 10.1021/acsnano.9b0484310.1021/acsnano.9b04843 ↗
28. 10.1016/j.mser.2019.03.00110.1016/j.mser.2019.03.001 ↗
29. 10.1002/adfm.20180433610.1002/adfm.201804336 ↗
30. 10.1021/acsami.0c0316610.1021/acsami.0c03166 ↗
31. 10.1021/acsami.9b0456910.1021/acsami.9b04569 ↗
32. 10.1021/acsami.7b1025610.1021/acsami.7b10256 ↗
33. 10.1016/j.biomaterials.2017.09.00610.1016/j.biomaterials.2017.09.006 ↗
34. 10.1038/ncomms1006610.1038/ncomms10066 ↗
35. 10.1038/ncomms1543210.1038/ncomms15432 ↗
36. 10.1002/adhm.20180031810.1002/adhm.201800318 ↗
37. 10.1002/adfm.20190706310.1002/adfm.201907063 ↗
38. 10.1021/acsnano.9b0786110.1021/acsnano.9b07861 ↗
39. 10.1021/acsami.7b1025610.1021/acsami.7b10256 ↗
40. 10.1245/ASO.2004.08.00310.1245/ASO.2004.08.003 ↗
41. 10.1016/j.jvir.2009.06.02910.1016/j.jvir.2009.06.029 ↗
42. 10.1002/advs.20170002410.1002/advs.201700024 ↗
43. 10.1007/BF0072117110.1007/BF00721171 ↗
44. 10.1007/s10853-010-5093-010.1007/s10853-010-5093-0 ↗
45. 10.1007/BF0264255910.1007/BF02642559 ↗
46. 10.1023/A:102258060100310.1023/A:1022580601003 ↗
47. Mei Z. Q. · J. Yangling Vocat. Tech. Coll. · 2002 · 1 · 9